Beau R. Webber

Department of Pediatrics, University of Minnesota

Research Area

Biography

Beau R. Webber has not added Biography.
If you are Beau R. Webber and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 2	Year
Publication title Cited by 13	2020
Publication title	2025

Other Publications

Article	Year
TALEN-based gene correction for epidermolysis bullosa. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 23546300	2013
DNA methylation of Runx1 regulatory regions correlates with transition from primitive to definitive hematopoietic potential in vitro and in vivo. Blood\| PubMed ID: 24030384	2013
Trp53 haploinsufficiency modifies EGFR-driven peripheral nerve sheath tumorigenesis. The American journal of pathology\| PubMed ID: 24832557	2014
Fanconi anemia gene editing by the CRISPR/Cas9 system. Human gene therapy\| PubMed ID: 25545896	2015
From marrow to matrix: novel gene and cell therapies for epidermolysis bullosa. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 25803200	2015
In Vitro T-Cell Generation From Adult, Embryonic, and Induced Pluripotent Stem Cells: Many Roads to One Destination. Stem cells (Dayton, Ohio)\| PubMed ID: 26227158	2015
Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 26502778	2016
CRISPR/Cas9 Targeted Gene Editing and Cellular Engineering in Fanconi Anemia. Stem cells and development\| PubMed ID: 27538887	2016
Angiotensin receptor blockade mediated amelioration of mucopolysaccharidosis type I cardiac and craniofacial pathology. Journal of inherited metabolic disease\| PubMed ID: 27743312	2017
CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa. NPJ Regenerative medicine\| PubMed ID: 28250968	2016
Aryl hydrocarbon receptor inhibition promotes hematolymphoid development from human pluripotent stem cells. Blood\| PubMed ID: 28533309	2017
CRISPR/Cas9-Mediated Correction of the FANCD1 Gene in Primary Patient Cells. International journal of molecular sciences\| PubMed ID: 28613254	2017
Dermatopontin in Bone Marrow Extracellular Matrix Regulates Adherence but Is Dispensable for Murine Hematopoietic Cell Maintenance. Stem cell reports\| PubMed ID: 28844660	2017
Rapid generation of Col7a1 mouse model of recessive dystrophic epidermolysis bullosa and partial rescue via immunosuppressive dermal mesenchymal stem cells. Laboratory investigation; a journal of technical methods and pathology\| PubMed ID: 28892093	2017
Rapid DNA replication origin licensing protects stem cell pluripotency. eLife\| PubMed ID: 29148972	2017
CRISPR/Cas9-Based Cellular Engineering for Targeted Gene Overexpression. International journal of molecular sciences\| PubMed ID: 29565806	2018
Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease. Scientific reports\| PubMed ID: 30108345	2018
Highly multiplexed genome engineering using CRISPR/Cas9 gRNA arrays. PloS one\| PubMed ID: 30222773	2018
EditR: A Method to Quantify Base Editing from Sanger Sequencing. The CRISPR journal\| PubMed ID: 31021262	2018
Base Editor Correction of COL7A1 in Recessive Dystrophic Epidermolysis Bullosa Patient-Derived Fibroblasts and iPSCs. The Journal of investigative dermatology\| PubMed ID: 31437443	2020
A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 31704085	2020
Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors. Nature communications\| PubMed ID: 31745080	2019
Author Correction: Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors. Nature communications\| PubMed ID: 31811147	2019
Efficient targeted integration directed by short homology in zebrafish and mammalian cells. eLife\| PubMed ID: 32412410	2020
CRISPR-Cas9 cytidine and adenosine base editing of splice-sites mediates highly-efficient disruption of proteins in primary and immortalized cells. Nature communications\| PubMed ID: 33893286	2021
Comparative international incidence of Ewing sarcoma 1988 to 2012. International journal of cancer\| PubMed ID: 33961701	2021
Engineering T cells to enhance 3D migration through structurally and mechanically complex tumor microenvironments. Nature communications\| PubMed ID: 33990566	2021
An irradiated marrow niche reveals a small noncollagenous protein mediator of homing, dermatopontin. Blood advances\| PubMed ID: 34448828	2021
MultiEditR: The first tool for the detection and quantification of RNA editing from Sanger sequencing demonstrates comparable fidelity to RNA-seq. Molecular therapy. Nucleic acids\| PubMed ID: 34589274	2021
A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers. Nature communications\| PubMed ID: 35017485	2022
Myosin Heavy Chain Converter Domain Mutations Drive Early-Stage Changes in Extracellular Matrix Dynamics in Hypertrophic Cardiomyopathy. Frontiers in cell and developmental biology\| PubMed ID: 35784482	2022
Correction of Fanconi Anemia Mutations Using Digital Genome Engineering. International journal of molecular sciences\| PubMed ID: 35955545	2022
Developing Bottom-Up Induced Pluripotent Stem Cell Derived Solid Tumor Models Using Precision Genome Editing Technologies. The CRISPR journal\| PubMed ID: 35972367	2022
Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade. Med (New York, N.Y.)\| PubMed ID: 36007524	2022
A Pan-RNase Inhibitor Enabling CRISPR-mRNA Platforms for Engineering of Primary Human Monocytes. International journal of molecular sciences\| PubMed ID: 36077152	2022
CRISPR-Cas9 base editors and their current role in human therapeutics. Cytotherapy\| PubMed ID: 36635153	2023
Germline T cell receptor exchange results in physiological T cell development and function. Nature communications\| PubMed ID: 36726009	2023
Ablation of SYK Kinase from Expanded Primary Human NK Cells via CRISPR/Cas9 Enhances Cytotoxicity and Cytokine Production. Journal of immunology (Baltimore, Md. : 1950)\| PubMed ID: 36881874	2023
Generation and characterization of an immunodeficient mouse model of mucopolysaccharidosis type II. Molecular genetics and metabolism\| PubMed ID: 37023503	2023
Cas9-induced targeted integration of large DNA payloads in primary human T cells via homology-mediated end-joining DNA repair. Nature biomedical engineering\| PubMed ID: 38092857	2024
Precision Enhancement of CAR-NK Cells through Non-Viral Engineering and Highly Multiplexed Base Editing. bioRxiv : the preprint server for biology\| PubMed ID: 38496503	2024
Evolution of the clinical-stage hyperactive TcBuster transposase as a platform for robust non-viral production of adoptive cellular therapies. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 38627969	2024
Development and testing of a versatile genome editing application reporter (V-GEAR) system. Molecular therapy. Methods & clinical development\| PubMed ID: 38764780	2024
Advancing gene targeting for primary immune deficiencies: Adenine base editing of the human IL2RG locus for correction of SCID-X1. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 38781958	2024
Engineering memory T cells as a platform for long-term enzyme replacement therapy in lysosomal storage disorders. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 39367605	2024
Efficient multiplex non-viral engineering and expansion of polyclonal γδ CAR-T cells for immunotherapy. bioRxiv : the preprint server for biology\| PubMed ID: 39464114	2024
Ablation of FAS confers allogeneic CD3 CAR T cells with resistance to rejection by T cells and natural killer cells. Nature biomedical engineering\| PubMed ID: 39558141	2024
CAR-T cell targeting three receptors on autoreactive B cells for systemic lupus erythematosus therapy. Journal of autoimmunity\| PubMed ID: 39832454	2025
Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre, phase 1 trial. The Lancet. Oncology\| PubMed ID: 40315882	2025
Precision enhancement of CAR-NK cells through non-viral engineering and highly multiplexed base editing. Journal for immunotherapy of cancer\| PubMed ID: 40341025	2025